Association of Antibiotic Exposure with Survival Outcomes in Patients with Advanced KRAS-Mutated NSCLC Receiving Immune Checkpoint Inhibitors
Translational Insights · 2026
DOI: 10.53941/ti.2026.100016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Insights, 2026. Verfasst von Qianlin Huang und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangzhou Science and Technology Program, National Natural Science Foundation of China, MOE Changjiang Distinguished Professor Supporting Project.
Abstract (Originalsprache)
Background
Antibiotic exposure has been associated with reduced benefit from immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer (NSCLC). However, evidence in patients with KRAS-mutated NSCLC remains limited. This study evaluated the associations of antibiotic and probiotic exposure with survival outcomes in patients with advanced KRAS-mutated NSCLC receiving ICIs.
Methods
This multicenter retrospective study included patients with advanced KRAS-mutated NSCLC who received at least one dose of ICI-based therapy. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared using the log-rank test. Univariable and multivariable Cox proportional hazards regression analyses were performed to evaluate factors associated with survival outcomes.
Results
A total of 101 patients were included, of whom 23 were exposed to antibiotics and 18 received probiotics. All patients had documented KRAS mutations. Eight patients received KRAS-targeted inhibitors after ICI progression, and none received KRAS-targeted inhibitors before or during ICI treatment. The median PFS was 9.0 months in the antibiotic-exposed group and 14.4 months in the non-antibiotic group (p = 0.041). The median OS was 23.5 and 38.4 months, respectively (p = 0.017). After multivariable adjustment, antibiotic exposure remained associated with shorter PFS (hazard ratio [HR], 2.04; 95% confidence interval [CI], 1.08–3.84; p = 0.029) and OS (HR, 2.85; 95% CI, 1.30–6.22; p = 0.009). Probiotic exposure was not significantly associated with PFS or OS.
Conclusions
Antibiotic exposure was associated with shorter PFS and OS in patients with advanced KRAS-mutated NSCLC receiving ICIs, whereas probiotic exposure was not significantly associated with survival outcomes.
Förderung
- Guangzhou Science and Technology Program
- National Natural Science Foundation of China
- MOE Changjiang Distinguished Professor Supporting Project
Zitieren
APA
Huang, Q., Luo, W., Zhang, Y., Chen, Z., Zhang, Q., Wang, F., Chang, J., & Zhou, Q. (2026). Association of Antibiotic Exposure with Survival Outcomes in Patients with Advanced KRAS-Mutated NSCLC Receiving Immune Checkpoint Inhibitors. Translational Insights. https://doi.org/10.53941/ti.2026.100016
Vancouver
Huang Q, Luo W, Zhang Y, Chen Z, Zhang Q, Wang F, et al. Association of Antibiotic Exposure with Survival Outcomes in Patients with Advanced KRAS-Mutated NSCLC Receiving Immune Checkpoint Inhibitors. Translational Insights. 2026. doi:10.53941/ti.2026.100016
BibTeX
@article{Huang2026,
author = {Huang, Qianlin and Luo, Weichi and Zhang, Yichen and Chen, Zhihong and Zhang, Qiuyi and Wang, Fen and Chang, Jianhua and Zhou, Qing},
title = {Association of Antibiotic Exposure with Survival Outcomes in Patients with Advanced KRAS-Mutated NSCLC Receiving Immune Checkpoint Inhibitors},
journal = {Translational Insights},
year = {2026},
doi = {10.53941/ti.2026.100016}
}
EUVIMED